Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls
To our knowledge, this is the largest longitudinal study to date of microdosing psilocybin and one of the few studies to engage a control group.
In light of these methodological strengths, the comparability of our findings with those of prior research from diverse locations and with different methodologies suggests a relatively consistent association between microdosing and improved mental health. Notably, the subgroup of respondents who reported mental health concerns at the time of baseline assessment exhibited an average reduction in depressive symptoms that resulted in a change from moderate to mild depression following approximately 30 days of microdosing psychedelics… Psychomotor performance and cognition Analyses of the finger tap test identified a main effect for microdosing, such that microdosers demonstrated a more positive change in performance than non-microdosers (F (1, 886) = 9.09, b = − 0.24, p = 0.03; Table 2). Supplementary analyses did not reveal a significant 3-way interaction across Microdose, Gender and Time, indicating that microdosing effects were consistent across Gender (F = 0.26, b = 0.94, p = 0.61). The effect of microdosing on tap score over time was robust to the removal of 16 outlier responses with scores 2 standard deviations from the mean (MicrodoseTime F = 7.23, b = − 0.21, p = 0.07), and treatment effects remained consistent when the study sample was limited to the 515 participants that were not microdosing at baseline (MicrodoseTime F = 5.07, b = 0.22, p = 0.03). Finally, the interaction between Microdose* Time*Age was not significant (F = 3.41, b = 0.43, p = 0.06), indicating that the effect of microdosing was consistent across age.
Original Article (Nature):
Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls
Artwork Fair Use: Peter de Lange
